Brief: Entrada Therapeutics Announces Updates On Entr-601-44 In Duchenne Muscular Dystrophy

Entrada Therapeutics

22/11/2023 12:29

Nov 22 (Reuters) - Entrada Therapeutics Inc  TRDA.O :
    * ENTRADA THERAPEUTICS ANNOUNCES UPDATES ON ENTR-601-44 IN
DUCHENNE MUSCULAR DYSTROPHY
    * ENTRADA THERAPEUTICS INC - CASH RUNWAY EXPECTED THROUGH
2025
    * ENTRADA THERAPEUTICS INC - PLANS TO ANNOUNCE DATA FROM
ENTR-601-44-101 IN SECOND HALF OF 2024
    * ENTRADA THERAPEUTICS INC - U.S. FDA CLINICAL HOLD ON IND
APPLICATION REMAINS IN EFFECT
    * ENTRADA THERAPEUTICS INC - COMPANY COMPLETES DOSING OF
FIRST AND
SECOND COHORTS IN PHASE 1 CLINICAL TRIAL, ENTR-601-44-101
    * ENTRADA THERAPEUTICS INC - WILL RE-ENGAGE FDA TO DISCUSS
NEXT
STEPS IN DUE COURSE

Source text for Eikon:  ID:nGNX3MnQQC 
Further company coverage:  TRDA.O 

 ((Reuters.Briefs@thomsonreuters.com;))